THE UK Competition and Markets Authority (CMA) slapped a "record" 84.2m fine on Pfizer, and a 5.2m fine on Flynn Pharma for their parts in charging "excessive and unfair" prices for epilepsy drug phenytoin sodium, with Pfizer planning to appeal, reports Chemist+Druggist.
The above article was sent to subscribers in Pharmacy Daily's issue from 09 Dec 16
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 09 Dec 16